OP5-005 Using Omnipod 5 in Adults With Type 2 (SECURE-T2D)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05815342 |
|
Recruitment Status :
Completed
First Posted : April 18, 2023
Last Update Posted : March 29, 2024
|
Sponsor:
Insulet Corporation
Collaborator:
Jaeb Center for Health Research
Information provided by (Responsible Party):
Insulet Corporation
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a single arm, multi-center, prospective study that will evaluate the safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes requiring insulin therapy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Type2 Diabetes | Device: Omnipod 5 Automated Glucose Control System | Not Applicable |
This outpatient study consists of 2 phases.
Phase 1 is a 14-day period to collect baseline glucose and insulin data. Participants will manage their diabetes as an outpatient per their usual routine. During this time participants will wear a blinded continuous glucose monitor to collect baseline glycemic information.
Phase 2 is a 13 week treatment period during which participants will use the Omnipod 5 System consisting of the Omnipod 5 pod, Omnipod 5 app as well as a Dexcom G6 continuous glucose monitor. Participants will do in-clinic or virtual visits at least monthly for a total of 8 visits. During the treatment period all participants will undergo supervised exercise and meal challenges.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 343 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes |
| Actual Study Start Date : | April 11, 2023 |
| Actual Primary Completion Date : | March 1, 2024 |
| Actual Study Completion Date : | March 1, 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Type 2 diabetes
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Treatment
All subjects wearing the Omnipod 5 Automated Glucose Monitoring System
|
Device: Omnipod 5 Automated Glucose Control System
The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery |
Primary Outcome Measures :
- Change in HbA1c [ Time Frame: Comparing the change in HbA1c during the 13 weeks study phase ]The change in HbA1c at 13 weeks from baseline
Secondary Outcome Measures :
- Mean Glucose [ Time Frame: Measuring mean glucose during the 13 weeks study phase ]Glucose metric from study provided continuous glucose monitor (CGM)
- Percentage of time in range 70-180 mg/dL [ Time Frame: Measured during 13 weeks study phase ]Glucose metric from CGM
- Percent of Time in Range 70-140 mg/dL [ Time Frame: Measured during 13 weeks study phase ]Glucose metric from study CGM
- Percent of Time ≥ 300 mg/dL [ Time Frame: Measured during 13 weeks study phase ]Glucose metric from CGM
- Percent of Time ≥ 250 mg/dL [ Time Frame: Measured during 13 weeks study phase ]Glucose metric from CGM
- Percent of Time >180 mg/dL [ Time Frame: Measured during 13 weeks study phase ]Glucose metric from CGM
- Percent of Time < 70 mg/dL [ Time Frame: Measured during 13 weeks study phase ]Glucose metric from CGM
- Percent of Time < 54 mg/dL [ Time Frame: Measured during 13 weeks study phase ]Glucose metric from CGM
- Change from baseline in T2-DDAS total score [ Time Frame: Baseline compared to end of week 13 visit ]A questionnaire that measures seven critical dimensions of distress (28-item scale with 6 choices that range from 1 (Not a Problem) to 6 (A Very Serious Problem)). The total score can range from 1 to 6, with a lower score indicating a better outcome.
- % Meeting MCID for T2-DDAS [ Time Frame: Baseline compared to end week 13 visit ]A questionnaire that measures seven critical dimensions of distress (28-item scale with 6 choices that range from 1 (Not a Problem) to 6 (A Very Serious Problem)). The total score can range from 1 to 6, with a lower score indicating a better outcome.
- Change from baseline in PSQI total score [ Time Frame: Baseline compared to end of week 13 visit ]Change from baseline in PSQI total score
- % Meeting MCID for PSQI [ Time Frame: Baseline compared to end of week 13 visit ]Change from baseline in PSQI total score
- Change from baseline in HCS total score [ Time Frame: Baseline compared to end week 13 visit ]Questionnaire that examines the degree to which people with diabetes feel able, secure, and comfortable regarding their ability to stay safe from hypoglycemic-related problems (9-item scale with 4 choices that range from 1 (Not Confident At All) to 4 (Very Confident)). The total score can range from 1 to 4, with a higher score indicating a better outcome.
- % Meeting MCID for HCS [ Time Frame: Baseline compared to end week 13 visit ]Questionnaire that examines the degree to which people with diabetes feel able, secure, and comfortable regarding their ability to stay safe from hypoglycemic-related problems (9-item scale with 4 choices that range from 1 (Not Confident At All) to 4 (Very Confident)). The total score can range from 1 to 4, with a higher score indicating a better outcome.
- Percentage of time <70 mg/dL [ Time Frame: Measured during 13 weeks study phase ]Glucose metric from CGM
- Percentage of time <54 mg/dL [ Time Frame: Measured during 13 weeks study phase ]Glucose metric from CGM
- Coefficient of variation [ Time Frame: Measured during 13 weeks study phase and compared to standard therapy ]Glucose metric from CGM measured glucose variability with the coefficient of variation (CV)
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age at time of consent 18-75 years
- Diagnosed with type 2 diabetes, on current insulin regimen for at least 3 months prior to screening (i.e. Basal-bolus, basal only or pre-mix)
- Basal bolus (long-acting insulin and rapid acting analog) or pre-mix users with A1C <12.0% OR basal users on long or intermediate acting insulin only with A1C > 7.0% and < 12.0%
- Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, or Admelog
- Participant agrees to provide their own insulin for the duration of the study
- Stable doses over the preceding 4 weeks of other glucose-lowering medications as determined by Investigator
- Stable doses of weight loss medications over the preceding 4 weeks and throughout the study that may affect glycemic control directly and/or indirectly, except for a dose reduction or discontinuation, as determined by Investigator
- Willing to wear the system continuously throughout the study
- Deemed appropriate for pump therapy per investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
- Investigator has confidence that the participant has the cognitive ability and can successfully operate all study devices and can adhere to the protocol
- Able to read and understand English or Spanish
- Willing and able to sign the Informed Consent Form (ICF)
- If female of childbearing potential, willing and able to have pregnancy testing
Exclusion Criteria:
- Use of an AID pump in automated mode within 3 months prior to screening
- Any medical condition which in the opinion of the investigator, would put the participant at an unacceptable safety risk, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, and/or eating disorders (i.e. anorexia/bulimia)
- Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening
- Any planned surgery during the study which could be considered major in the opinion of the investigator
- History of more than 1 severe hypoglycemic event in the 6 months prior to screening
- History of more than 1 episode of diabetic ketoacidosis (DKA) or Hyperosmolar hyperglycemic syndrome (HHS) in the 6 months prior to screening; unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis
- Blood disorder or dyscrasia within 3 months prior to screening, including use of hydroxyurea, which in the investigator's opinion could interfere with determination of HbA1c
- Plans to receive blood transfusion over the course of the study
- Has taken oral or injectable steroids within 8 weeks prior to screening or plans to take oral or injectable steroids during the study
- Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement
- Pregnant or lactating, planning to become pregnant during the study, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal)
- Participation in another clinical study using an investigational drug or device other than the Omnipod 5 in the 30 days prior to screening or intends to participate during the study period
- Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment
- Participant is an employee of Insulet, an Investigator or Investigator's study team, or immediate family member (spouse, biological or legal guardian, child, sibling, parent) of any of the aforementioned
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05815342
Locations
Show 21 study locations
Sponsors and Collaborators
Insulet Corporation
Jaeb Center for Health Research
Investigators
| Study Chair: | Francisco J Pasquel, MD | Emory School of Medicine |
| Responsible Party: | Insulet Corporation |
| ClinicalTrials.gov Identifier: | NCT05815342 |
| Other Study ID Numbers: |
G230013 |
| First Posted: | April 18, 2023 Key Record Dates |
| Last Update Posted: | March 29, 2024 |
| Last Verified: | March 2024 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
Keywords provided by Insulet Corporation:
|
T2D Omnipod Automated Insulin Delivery |
Additional relevant MeSH terms:
|
Diabetes Mellitus, Type 2 Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |